AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03616223
Drug: FX-322
RxNorm normalized name: Prevail-FX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratympanic injection of FX-322 consists of laduviglusib and sodium valproate
Trial: NCT03616223
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratympanic injection
Trial: NCT04713527
Drug: Enteral antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with complicated appendicitis will receive enteral antibiotics instead of intravenous
Trial: NCT01523301
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal Patch~Size:~10 cm\^2, 20 cm\^2, 30 cm\^2, 40 cm\^2~Subjects randomized to placebo received matching placebo patches
Trial: NCT01087801
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline for Injection
Trial: NCT01684306
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.
Trial: NCT02912884
Drug: No cytoreductive vs cytoreductive drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No cytoreductive treatment vs cytoreductive drugs (hydroxycarbamide, alpha-interferon, ruxolitinib).
Trial: NCT01447628
Drug: Ferinject or CosmoFer
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous, 1000 mg iron
Trial: NCT03087773
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject will receive Placebo orally once daily for 26 weeks.
Trial: NCT02341794
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin (5mg) will be orally administrated once daily. Dose of rosuvastatin will be adjusted to control serum LDL-c level under 1.8 mmol/L.
Trial: NCT04149015
Drug: paclitaxel ,oxaliplatin,fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 4 cycles.
Trial: NCT04512339
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections (blinded labels), matching the dupilumab injections in quantity and appearance
Trial: NCT03558984
Drug: D-PLEX
RxNorm normalized name: Kleer Plex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-PLEX is a new formulation of extended release of Doxycycline (active ingredient)
Trial: NCT00025727
Drug: GW433908
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04592731
Drug: Vehicle Gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The vehicle gel contains no acetylated natural nucleotides but with the same base as study drug.
Trial: NCT00895011
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose 30 minutes prior to initiation of sexual activity
Trial: NCT01430754
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules, daily
Trial: NCT05586711
Drug: vaginal DHEA 6.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrarosa® (dehydroepiandrosterone; DHEA; prasterone), pessaries
Trial: NCT01343823
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as two SC 3 mL injections
Trial: NCT00177047
Drug: Cyclophosphamide + Mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide: 4mg/m\^2 + Mesna. Mesna is used to reduce the undesired side effects of certain chemotherapy drugs.
Trial: NCT00923364
Drug: Cyclophosphamide (CTX, Cytoxan)
RxNorm normalized name: cyclophosphamide Oral Tablet [Cytoxan]
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 14.5 mg/kg intravenous (IV) (in the vein) infusion over 30 minutes once daily on days -6 and -5 (weight based dosing) or 50 mg/kg IV infusion over 2 hours on day -6 (weight based dosing) or 50/kg IV once daily x 2 doses on days +3 and +4
Trial: NCT01011478
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02618824
Drug: Histidine Tryptophan Ketoglutarate Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hearts will be arrested with Histidine Tryptophan Ketoglutarate (HTK) solution during cardiac operation. After aortic cross clamp 50-60 ml/kg HTK will be administered
Trial: NCT01463332
Drug: I.V injection of 10 ml normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group NS were injected intravenously with 10 ml of normal saline before injection of propofol.
Trial: NCT03044639
Drug: Lipid Emulsions, Intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The every day provision of lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
Trial: NCT01039025
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After stem cells are collected, Cyclophosphamide 1 g/m\^2/day intravenously given over 2 hours on Days 1 - 3.
Trial: NCT03600623
Drug: Folfirinox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBRT will follow Folfirinox at the completion of Cycle 2 (if eligible).
Trial: NCT00671359
Drug: TR-701 600mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TR-701 600mg
Trial: NCT00075270
Drug: GW572016 (Lapatinib)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral GW572016 Lapatinib
Trial: NCT01843647
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After surgery patients receive 4-cycle adjuvant chemotherapy with vinorelbine~/cisplatin regimen, until untolerable toxicity or disease progression.
Trial: NCT01568528
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The PBO/control will consist of the OT vehicle only delivered as 3 puffs of saline per nostril for a total of 6 puffs. Each puff contains 0.1 ml in volume, so the total delivered will be 0.6 ml intranasally.
Trial: NCT00663611
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline
Trial: NCT00308347
Drug: Placebo / Duration of Treatment: mean 3.4 years
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04399746
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500mg once daily for 4 days
Trial: NCT04164693
Drug: Low molecular weight heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients began to use low molecular weight heparin or warfarin sodium tablets.
Trial: NCT02513147
Drug: 2 NRTI
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06441526
Drug: anti-tumour necrosis factor α antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological drug
Trial: NCT00179166
Drug: TPN nutritional supplement
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous administration of nutritional supplement for 4 hours at a dosage of 30 kcal/kg/day, in the form of lipids, carbohydrates and protein; the non-protein calories are comprised of lipids (30%) and carbohydrates (70%)
Trial: NCT03920722
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-Rituximab 1 gram IV on Day 1 and 15 after premedication with 100 mg méthylprednisolone, 1 gramm paracetamol and 5 mg dexchlorpheniramine
Trial: NCT00221052
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00274924
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00274924
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00803530
Drug: ATO + Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ATO will be diluted in 250 ml of normal saline solution at a dosage of 0.3 mg/Kg during the first week of therapy and at a dosage of 0.25 mg/Kg during the subsequent weeks (week 2 to 16), and administered intravenously over a 1-2 hour period.~The dose of ascorbic acid will be 1000 mg in 100 cc D5W or normal saline solution (NaCl 0.9 %) (protected from light and air) administered as an IV infusion over 15 to 30 minutes. The dosing solution is not to be mixed with any alkaline solution.
Trial: NCT00116207
Drug: ORAL ANTIOXIDANT
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of triple antioxidant combination therapy vs placebo.
Trial: NCT03412994
Drug: standard second-line chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The second line standard chemotherapy regimen recommended by the NCCN
Trial: NCT02102022
Drug: ADI-PEG 20 plus modified FOLFOX6
RxNorm normalized name: PEG-20 stearate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00179218
Drug: nutritional supplementation
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration of 2 cans of protein supplement (lactose-free formula that contains a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat); every other day, 3 days per week, for 6 months
Trial: NCT02311543
Drug: TachoSil® patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TachoSil® is a sterile, ready-to-use, absorbable surgical patch and consists of an equine collagen sponge coated with human fibrinogen and human thrombin.
Trial: NCT03789058
Drug: Ibuprofen 400 mg
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Surgical removal of wisdom teethb with different regimen of Ibuprofen frequency ; three times versus two times .
Trial: NCT00155259
Drug: Docetaxel , Cisplatin , Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02962869
Drug: BAY987517
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 μl/ cm\*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. Twenty-four (24) hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm\*2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. Forty-eight (48) hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. (Formulation number: Z43-078)
Trial: NCT00533585
Drug: BAY 43-9006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting Dose of 200 mg orally twice a day on Day 3 through Day 19 of Cycle 1 and Days 2 through 19 of Cycle 2 and remaining cycles. Cycle is 21 days.
Trial: NCT01230853
Drug: Placebo Comparator B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Matching Placebo Infusion
Trial: NCT01230853
Drug: Active Comparator B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lecanemab Multiple Dose Ascending Intravenous infusions once every 4 weeks at sequentially ascending doses (dose levels: 0.3, 1, 3, and 10 mg/kg)
Trial: NCT04676971
Drug: hzVSF-v13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form: 100mg / 200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1, 3, 7, D14(if necessary)
Trial: NCT01230853
Drug: Placebo Comparator A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Matching Placebo Infusion
Trial: NCT02231788
Drug: Telminuvo®Tab. 40/2.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telminuvo®Tab. 40/2.5mg, Once daily, Per oral for 8weeks after 2\~4weeks run-in period with Telmitrend®Tab. 40mg
Trial: NCT00730431
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo supplied as size 3, white opaque capsules matching IDX184 capsules.
Trial: NCT01609478
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo delivered via Concept 1 inhaler
Trial: NCT02737033
Drug: Rhodiola
RxNorm normalized name: RHODIOLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhodiola rosea 800mg
Trial: NCT02737033
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: innocuous pill manufactured to mimic Rhodiola
Trial: NCT02426125
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT03080077
Drug: Ricrolin+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The IONTOPHOR CXL iontophoresis applicator and the associated blepharostat will be placed onto the cornea to be treated. The applicator will be secured to the cornea and filled with Ricrolin+ which as been aspirated from the bottle using a syringe with a needle. The generator will be switched on and set to 1 mA for 5 minutes. The generator will then be disconnected and the applicator will be removed from the cornea.
Trial: NCT03080077
Drug: Epi-Off
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using topical anesthesia (proparacaine), the surgeon will create a complete corneal abrasion to facilitate riboflavin diffusion into the cornea. The epithelium will be removed by gently brushing the cornea with a scalpel. A corneal abrasion diameter of \~9mm is recommended, which may be adjusted as needed at the discretion of the investigator to accommodate individual eye geometry. Ultrasound corneal pachymetry should be performed before dis-epithelialization and after dis- epithelialization. Local anesthetics will be administered as needed to maintain patient comfort during the CXL procedure.
Trial: NCT04141670
Drug: S48168
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A novel oral small molecule which is designed to repair leaky RYR1 channels
Trial: NCT02578368
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m², d1, i.v., every 2 weeks
Trial: NCT01119352
Drug: AZD7687
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral suspension, once daily. Starting dose of 1mg and with up to 4 dose escalations. Totally 8 doses.
Trial: NCT03706924
Drug: VM-1500FDC
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A fixed-dose combination of three active substances: tenofovir 300 mg + elsulfavirine 20 mg + emtricitabine 200 mg, film-coated tablets
Trial: NCT03706924
Drug: Elpida®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elpida®, capsules, elsulfavirine 20 mg
Trial: NCT03706924
Drug: Truvada®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Truvada® (tenofovir 300 mg / emtricitabine 200 mg), film-coated tablets
Trial: NCT00663247
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 grams daily for 3 months
Trial: NCT01658813
Drug: 5-Fluorouracil and Interferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-Fluorouracil Interferon-alfa-2b
Trial: NCT00938886
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched naltrexone placebo
Trial: NCT03415386
Drug: Combination of antiplatelet drugs and anticoagulants for at least one month
RxNorm normalized name: omega-3 acid ethyl esters (USP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of antiplatelet drugs and anticoagulants for at least one month, such as aspirin100mg qd+clopidogrel75mg qd+warfarin (INR1.8-2.2), aspirin100mg qd+clopidogrel75mg qd+dabigatran110mg bid, aspirin100mg qd+ticagrelor60mg bid+warfarin (INR1.8-2.2), and aspirin100mg qd+ticagrelor60mg bid+dabigatran110mg bid. Transthoracic two-dimensional echocardiography will be done at the 1-month, 3-month and 6-month follow-ups to evaluate the left ventricular mural thrombus and determinate whether the antithrombotic therapy regimen could be regulated to double antiplatelet or anticoagulant+clopidogrel75mg qd/ticagrelor60mg bid.
Trial: NCT01146860
Drug: BNO 1016
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar coated tablets with dry extract (80 mg) of 5 herbal drugs; dosage: 480 mg per day (2 tablets t.i.d.) duration: 15 days
Trial: NCT01146860
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar coated tablets with identical appearance to active treatment; frequency: 2 tablets t.i.d. duration 15 days
Trial: NCT02306031
Drug: Prescribe ARTIFICIAL TEAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: From one week before surgery, and control group received artificial tear (Sina Darou Laboratories Company, Tehran, Iran) as a placebo every 6 hours. Theses drops continued up to 6 weeks with the same dose after operations
Trial: NCT02306031
Drug: Prescribe diclofenac sodium drop 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: From one week before surgery, case group received diclofenac sodium drop 0.1% (Sina Darou Laboratories Company, Tehran, Iran) every 6 hours.Theses drops continued up to 6 weeks with the same dose after operations
Trial: NCT01341392
Drug: amlodiopine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
Trial: NCT04493840
Drug: Shenfu Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80ml Shenfu Injection + 70ml 5% glucose injection, ivdrip, within 30 minutes before PCI and 1 to 5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
Trial: NCT04493840
Drug: 5% Glucose Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 ml 5% glucose injection, ivdrip, within 30 minutes before PCI and 1 to 5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
Trial: NCT00303134
Drug: Islet Cell Transplantation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Islet Cell Transplantation for patients with type 1 diabetes mellitus
Trial: NCT00160446
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral Daily for 12 weeks
Trial: NCT02463552
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patient will receive a single-dose of Naproxen (500 mg) one hour before the bleaching procedure.
Trial: NCT02674854
Drug: PG324 Ophthalmic Solution 0.02%/0.005%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop daily in the evening (PM) in both eyes (OU)
Trial: NCT03791515
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A randomized clinical trial with a double-blinded, randomized, placebo-controlled crossover design. 30 PPTH patients will be included. All participants will receive continuous intravenous infusion of 40 mL placebo (isotonic saline) over 20 min.~The following variables will be recorded before, during and after infusion (every 10 min over 60 min): headache intensity on a verbal rating scale from 0 to 10 and headache characteristics. At 90 min, participants will be discharged and instructed to fill out a headache diary for 24 hours from start of infusion.
Trial: NCT00344942
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a double spray into each nostril once daily
Trial: NCT00913692
Drug: Glycine
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects were randomized to take one of the study agents, 15 gm by mouth twice daily for 5 months. After a 2 week washout period, subjects began the other agent at 15 gm by mouth twice daily for 5 months.
Trial: NCT02582177
Drug: Candicort®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply on the affected area and around it twice a day
Trial: NCT02582177
Drug: Nizoral®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply on the affected area and around it twice a day
Trial: NCT02582177
Drug: Baycuten N®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply on the affected area and around it twice a day
Trial: NCT02582177
Drug: Canesten®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply on the affected area and around it twice a day
Trial: NCT01767311
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: biweekly (once every 2 weeks) administered as i.v. infusion
Trial: NCT01059929
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Trial: NCT04456153
Drug: Experimental Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued standard of care therapy together with an oral dose of 1500 mg atovaquone twice daily (administered with a meal or snack) for up to 10 days
Trial: NCT04456153
Drug: Placebo Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued standard of care therapy together with matching placebo
Trial: NCT00251004
Drug: Mycophenolic Acid (MPA)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 oral capsules of mycophenolic acid 360mg administered bid
Trial: NCT02737072
Drug: LY2510924
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SQ